Vtv Therapeutics Inc. reported that its oral GLP-1 receptor agonist, TTP273, helped type 2 diabetics on stable doses of metformin achieve mean placebo-subtracted HbA1c differences of up to -0.86 percent during a phase II study, giving it confidence to continue advancing the program, one of two diabetes-focused efforts at the company.